

Clinical Psychiatry



Coordinator

Portella Moll, María Jesús IR
mportella@santpau.cat

Members

Allende Leal, Saiko	CIBERSAM
Almenta Gallego, David	FGS
Alonso Solís, Anna	IR
Álvarez Martínez, Enric	FGS
Carceller Sindreu, Maria del Mar	IR
Carmona Farres, Cristina	IR
Corripio Collado, Iluminada	FGS
De Diego Adeliño, Francisco Javier	FGS
Díaz Pérez, Anna Maria	FGS
Draganov, Metodi	IR
Fernández Vidal, Aina	FGS
García-Ribera Comdor, Carles	FGS
Grasa Bello, Eva Maria	CIBERSAM
Jubero Urgell, Miriam	IR
Pascual Mateos, Juan Carlos	FGS
Pérez Blanco, Josefina	FGS
Pérez Sola, Victor	FGS
Puigdemont Campos, Maria Dolors	FGS
Rabella Figueras, Mireia	IR
Soler Ribaudi, Joaquín	FGS
Soriano Pacheco, José Antonio	FGS
Tiana Sastre, Thaís	FGS
Vicent Gil, Muriel	IR

Main Lines of Research

- ▶ Psychotic disorders (first episodes and persistent hallucinations).
- ▶ Affective disorders (major depression and validation of scales).
- ▶ Borderline personality disorder.

Challenges

- ▶ Foster research that reduces the health-care, social and personal costs of mental illness by exploring areas such as epidemiology, etiopathogenesis, physiopathology, prevention and treatment.
- ▶ Foster research into mental health therapies.
- ▶ Foster research to improve quality of life of patients with mental disorders.

Research into Psychotic Disorders

- ▶ Neuroimaging studies in first psychotic episodes.
- ▶ Study of environmental, biological and genetic factors in psychosis.
- ▶ Efficacy and effectiveness studies of anti-psychotic drugs.
- ▶ Efficacy and effectiveness study of psychotherapy for hallucinations.
- ▶ Study of treatment resistance in schizophrenia.

Research into Affective Disorders

- ▶ Identification and evaluation of new therapeutic targets in depression.
- ▶ Neuroimaging studies in first psychotic episodes.
- ▶ Biological and genetic markers in affective disorders.
- ▶ Implementation of new therapeutic programmes, depression evaluation and social aspects of depression.

Research into Personality Disorders

- ▶ Clinical trials regarding the usefulness of mixed treatment in patients with borderline personality disorder and validation of diagnostic instruments.
- ▶ Genetic-neuroimaging studies of borderline personality disorder (BPD).
- ▶ Efficacy and effectiveness studies of psychotherapy for treating borderline personality disorder.

Collaborations

Collaborations with other IIB Sant Pau Groups

- ▶ Addictive Behaviours.
- ▶ Neuroradiology.
- ▶ Neurosurgery.
- ▶ Hypophysis Diseases.
- ▶ CIM – Sant Pau.
- ▶ Pain Clinic Sant Pau.
- ▶ Genetics.
- ▶ Internal Medicine.

External Collaborations

- ▶ Hospital Clínic de Barcelona, Psychiatry Department.
- ▶ Hospital Parc Taulí, Sabadell, Psychiatry Department.
- ▶ Universidad Complutense de Madrid, Medicine-Pharmacology Department.
- ▶ Hospital Universitario de la Princesa, Madrid, Psychiatry Department.
- ▶ Universidad de Valencia, Medicine-Psychiatry Department.
- ▶ Leipzig University, Medicine-Psychiatry Department.
- ▶ Universidad de Cádiz, Medicine-Pharmacology Department.
- ▶ Hospital Benito Menni – FIDMAG, Barcelona, Psychiatry Department.
- ▶ University of Oxford, Medicine-Psychiatry Department.

Active Grants

- ▶ Maria Jesús Portella Moll. Estudio longitudinal de cambios cerebrales en pacientes con un primer episodio de depresión mayor. PI13/01057. Instituto de Salud Carlos III. Duration: 2014-2018. 56,300.00 €.
- ▶ Joaquín Soler Ribaudi. Efectos del Mindfulness en la Actividad y Conectividad Funcional de la Default Mode Network en Pacientes con Trastorno Límite de la Personalidad. PI13/00134. Instituto de Salud Carlos III. Duration: 2014-2017. 46,150.00 €.
- ▶ Iluminada Corripio Collado. Mobile Therapeutic Attention for Patients with Treatment Resistant Schizophrenia (m-RESIST). PHC26-2014 (2) - IR. Unió Europea. Duration: 2015-2017. 126,474.19 €.
- ▶ Juan Carlos Pascual Mateos. Estudio Epigenómico en el Trastorno Límite de la Personalidad: estudio del patrón de metilación (EWAS-Epigenome-wide association study) y su relación con antecedentes traumáticos. PI14/00214. Instituto de Salud Carlos III. Duration: 2015-2018. 81,500.00 €.
- ▶ Eva María Grasa Bello. Eficacia del Entrenamiento Metacognitivo Individualizado (EMC+) en personas con psicosis de breve evolución. PI14/00044 C. Instituto de Salud Carlos III. Duration: 2015-2017.
- ▶ Iluminada Corripio Collado. Mobile Therapeutic Attention for Patients with Treatment Resistant Schizophrenia (m-RESIST). PHC26-2014 (2) - FGS. Unió Europea. Duration: 2015-2017. 152,667.81 €.
- ▶ Francisco Javier de Diego Adeliño. Estudio longitudinal de predicción precoz de la respuesta en depresión con la combinación multimodal de biomarcadores epigenéticos, neurocognitivos y clínicos. PI16/00302. Instituto de Salud Carlos III. Duration: 2017-2019. 86,500.00 €.
- ▶ Enric Álvarez Martínez. Efectos de un análogo de la Ayahuasca sobre el reprocesamiento emocional en pacientes con Trastorno Límite de la Personalidad. PI16/00078. Instituto de Salud Carlos III. Duration: 2017-2019. 46,500.00 €.
- ▶ Maria Jesús Portella Moll. Contractes "Miguel Servet II" 2016. CPII16/00020. Instituto de Salud Carlos III. Duration: 2017-2020. 101,250.00 €.
- ▶ Maria Jesús Portella Moll. Convocatòria d'ajuts intramurals per cofinançar despeses pel desenvolupament de projectes actius 2016. IR16-P3. Fundació Privada Hospital de la Santa Creu i Sant Pau. Duration: 2017-2017. 7,000.00 €.
- ▶ Enric Álvarez Martínez. Estimulación Cerebral Profunda en el tratamiento de la esquizofrenia refractaria: Estudio piloto aleatorizado, controlado y cruzado. PI12/00042. Instituto de Salud Carlos III. Duration: 2013-2017. 91,500.00 €.
- ▶ Maria Jesús Portella Moll. Contracte SNS "M. SERVET" 2010. MS10/00393. Instituto de Salud Carlos III. Duration: 2011-2017. 151,875.00 €.
- ▶ Maria del Mar Carceller Sindreu. Contractes predoctorals de formació en investigació en salut 2014. FI14/00201. Instituto de Salud Carlos III. Duration: 2015-2019. 82,400.00 €.
- ▶ Francisco Javier de Diego Adeliño. Contratos Juan Rodés 2014. JR14/00011. Instituto de Salud Carlos III. Duration: 2015-2018. 135,000.00 €.
- ▶ Lorena Chanes Puiggrós. Contractes postdoctorals "Sara Borrell" 2016. CD16/00059. Instituto de Salud Carlos III. Duration: 2017-2019. 80,598.00 €.
- ▶ Maria Jesús Portella Moll. Grup de Recerca en Trastorns Psiquiàtrics de Sant Pau. 2017 SGR 1343. Agència de Gestió d'Ajuts Universitaris i de Recerca. Duration: 2017-2019. 16,250.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

Grants Awarded in 2017

- ▶ Maria Jesús Portella Moll. RIDEM: Rehabilitación Integral para Depresión Mayor. Estudio de eficacia de un programa de rehabilitación integral. PI17/00056. Instituto de Salud Carlos III. Duration: 2018-2020. 47,000.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

Theses

- ▶ Anna Barata Badiella. Qualitat de vida en el receptor de trasplantament hematopoiètic. Universitat Autònoma de Barcelona. Directors: Jim Heather, Rodrigo Martino, Jordi Sierra and Enric Álvarez (tutor). Date of defense: 15/03/2017.

Clinical Psychiatry

*TIF: 95.2194 **MIF: 2.9756

Alonso-Solis A., Vives-Gilbert Y., Portella M.J., Rabella M., Grasa E.M., Roldan A., Keymer-Gausset A., Molins C., Nunez-Marin F., Gomez-Anson B., Alvarez E., Corripio I., Altered amplitude of low frequency fluctuations in schizophrenia patients with persistent auditory verbal hallucinations (2017) SCHIZOPHR RES, 189, 97-103.

IF: 3.649

Alvarez-Tomas I., Soler J., Bados A., Martin-Blanco A., Elices M., Carmona C., Bauza J., Pascual J.C., Long-term course of borderline personality disorder: A prospective 10-year follow-up study (2017) J PERS DISORD, 31 (5), 590-605.

IF: 2.471

Bernardo M., Bioque M., Cabrera B., Lobo A., Gonzalez-Pinto A., Pina L., Corripio I., Sanjuan J., Mane A., Castro-Fornieles J., Vieta E., Arango C., Mezquida G., Gasso P., Parellada M., Saiz-Ruiz J., Cuesta M.J., Mas S., Modelling gene-environment interaction in first episodes of psychosis (2017) SCHIZOPHR RES, 189, 181-189.

IF: 3.649

Carceller-Sindreu M., de Diego-Adelino J., Portella M.J., Garcia-Moll X., Figueras M., Fernandez-Vidal A., Queralto J.M., Puigdemont D., Alvarez E., Lack of relationship between plasma levels of escitalopram and QTc-interval length (2017) EUR ARCH PSY CLIN N, 267 (8), 815-822.

IF: 3.617

Cebolla A., Campos D., Galiana L., Oliver A., Tomas J.M., Feliu-Soler A., Soler J., Garcia-Campayo J., Demarzo M., Banos R.M., Exploring relations among mindfulness facets and various meditation practices: Do they work in different ways? (2017) CONSCIOUS COGN, 49, 172-180.

IF: 2.003

Cebolla A., Demarzo M., Martins P., Soler J., Garcia-Campayo J., Unwanted effects: Is there a negative side of meditation? A multicentre survey (2017) PLOS ONE, 12 (9).

IF: 2.600

Elices M., Carmona C., Narvaez V., Seto V., Martin-Blanco A., Pascual J.C., Soriano J., Soler J., Direct experience while eating: Laboratory outcomes among individuals with eating disorders versus healthy controls (2017) EAT BEHAV, 27, 23-26.

IF: 1.870

Escandon-Nagel N., Dada G., Grau A., Soriano J., Feixas G., Eating disorder patients evolution three years after intake in Day Hospital La evolución de los pacientes con trastorno de la conducta alimentaria tres años después de ingresar a Hospital de Día (2017) REV ARGENT CLIN PSIC, 16 (1), 59-69.

IF: 0.436

Estrada-Prat X., Alvarez-Guerrico I., Bleda-Hernandez M.J., Camprodon-Rosanas E., Batlle-Vila S., Pujals-Altes E., Nascimento-Osorio M.T., Martin-Lopez L.M., Alvarez-Martinez E., Perez-Sola V., Romero-Cela S., Sleep study in disruptive mood dysregulation disorder and bipolar children Estudio del sueño en niños con Trastorno de Disregulación Disruptivo del Estado de Ánimo y Bipolares (2017) ACTAS ESP PSIQUIATRI, 45 (1), 12-20.

IF: 0.796

Feliu-Soler A., Pascual J.C., Elices M., Martin-Blanco A., Carmona C., Cebolla A., Simon V., Soler J., Fostering Self-Compassion and Loving-Kindness in Patients With Borderline Personality Disorder: A Randomized Pilot Study (2017) CLIN PSYCHOL PSYCHOT, 24 (1), 278-286.

IF: 2.263

Fraguas D., Diaz-Caneja C.M., Corripio I., Gonzalez-Pinto A., Lobo A., Bioque M., Cuesta M.J., Sanjuan J., Rodriguez-Toscano E., Arias B., Sarro S., Cabrera B., Bulbena A., Vieta E., Castro-Fornieles J., Arango C., Bernardo M., Parellada M., Gene-environment interaction as a predictor of early adjustment in first episode psychosis (2017) SCHIZOPHR RES, 189, 196-203.

IF: 3.649

Franquesa A., Cebolla A., Garcia-Campayo J., Demarzo M., Elices M., Pascual J.C., Soler J., Meditation Practice Is Associated with a Values-Oriented Life: the Mediating Role of Decentering and Mindfulness (2017) MINDFULNESS, 8 (5), 1259-1268.

IF: 2.474

Garriga M., Sole E., Gonzalez-Pinto A., Selva-Vera G., Arranz B., Amann B.L., Saiz-Ruiz J., Perez-Blanco J., Vieta E., Efficacy of quetiapine XR vs. placebo as concomitant treatment to mood stabilizers in the control of subthreshold symptoms of bipolar disorder: Results from a pilot, randomized controlled trial (2017) EUR NEUROPSYCHOPHARM, 27 (10), 959-969.

IF: 3.946

Huerta-Ramos E., Marco-Garcia S., Soledad-Escobar-Villegas M., Rubio-Abadal E., Ochoa S., GrasaBello E.M., Solis A.A., Rabella M., Berdun J., Hospedales M., Corripio I., Usall J., M-RESIST, a complete m-Health solution for patients with treatment-resistant schizophrenia: A qualitative study of user needs and acceptability in the Barcelona metropolitan area M-RESIST, una solución m-health integral para personas con esquizofrenia resistente: Estudio cualitativo de necesidades y aceptabilidad de usuarios en el área de Barcelona (2017) ACTAS ESP PSIQUIATRI, 45 (6), 277-289.

IF: 0.796

Justicia A., Elices M., Cebria A.I., Palao D.J., Gorosabel J., Puigdemont D., de Diego-Adelino J., Gabilondo A., Iruin A., Hegerl U., Perez V., Rationale and methods of the iFightDepression study: A double-blind, randomized controlled trial evaluating the efficacy of an internet-based self-management tool for moderate to mild depression (2017) BMC PSYCHIATRY, 17 (1).

IF: 2.419

Justicia A., Elices M., Cebria A.I., Palao D.J., Gorosabel J., Puigdemont D., de Diego-Adelino J., Gabilondo A., Iruin A., Hegerl U., Perez V., Rationale and methods of the iFightDepression study: A double-blind, randomized controlled trial evaluating the efficacy of an internet-based self-management tool for moderate to mild depression (2017) BMC PSYCHIATRY, 17 (1).

IF: 2.280

Mane A., Berge D., Penzol M.J., Parellada M., Bioque M., Lobo A., Gonzalez-Pinto A., Corripio I., Cabrera B., Saiz-Ruiz J., Bernardo M., Cannabis use, COMT, BDNF and age at first-episode psychosis (2017) PSYCHIAT RES, 250, 38-43.

IF: 2.223

Martin-Blanco A., Patrizi B., Soler J., Gasol X., Elices M., Gasol M., Carmona C., Pascual J.C., Use of nalmefene in patients with comorbid borderline personality disorder and alcohol use disorder: A preliminary report (2017) INT CLIN PSYCHOPHARM, 32 (4), 231-234.

IF: 2.284

Martin-Blanco A., Ancochea A., Soler J., Elices M., Carmona C., Pascual J.C., Changes over the last 15 years in the psychopharmacological management of persons with borderline personality disorder (2017) ACTA PSYCHIAT SCAND, 136 (3), 323-331.

IF: 4.772

Mas S., Gasso P., Torra M., Bioque M., Lobo A., Gonzalez-Pinto A., Olmeda M.S., Corripio I., Vieta E., Castro-Fornieles J., Rodriguez-Jimenez R., Bobes J., Usall J., Llerena A., Saiz-Ruiz J., Bernardo M., Lafuente A., Intuitive pharmacogenetic dosing of risperidone according to CYP2D6 phenotype extrapolated from genotype in a cohort of first episode psychosis patients (2017) EUR NEUROPSYCHOPHARM, 27 (7), 647-656.

IF: 3.946

Mezquida G., Cabrera B., Bioque M., Amoretti S., Lobo A., Gonzalez-Pinto A., Espliego A., Corripio I., Vieta E., Castro-Fornieles J., Berge D., Escarti M.J., Ibanez A., Penades R., Sanchez-Torres A.M., Bernardo M., The course of negative symptoms in first-episode schizophrenia and its predictors: A prospective two-year follow-up study (2017) SCHIZOPHR RES, 189, 84-90.

IF: 3.649

*TIF: 95.2194 **MIF: 2.9756

Scientific Production

Molins C., Carceller-Sindreu M., Navarro H., Carmona C., Pineiro M., Martinez E., Alvarez E., Portella M.J., Plasma ratio of clozapine to N-desmethylclozapine can predict cognitive performance in treatment-resistant psychotic patients (2017) *PSYCHIAT RES*, 258, 153-157.

IF: 2.325

Mora E., Portella M.J., Martinez-Alonso M., Teres M., Forcada I., Vieta E., Mur M., The impact of obesity on cognitive functioning in euthymic bipolar patients: A cross-sectional and longitudinal study (2017) *J CLIN PSYCHIAT*, 78 (8), e924-e932.

IF: 4.058

Ochoa S., Lopez-Carrilero R., Barrigon M.L., Pousa E., Barajas A., Lorente-Rovira E., Gonzalez-Higuera F., Grasa E., Ruiz-Delgado I., Cid J., Birules I., Esteban-Pinos I., Casanas R., Luengo A., Torres-Hernandez P., Corripio I., Montes-Gamez M., Beltran M., De Apraiz A., Dominguez-Sanchez L., Sanchez E., Llacer B., Pelaez T., Bogas J.L., Moritz S., Randomized control trial to assess the efficacy of meta-cognitive training compared with a psycho-educational group in people with a recent-onset psychosis (2017) *PSYCHOL MED*, 47 (9), 1573-1584.

IF: 5.296

Perez V., Salavert A., Espadaler J., Tuson M., Saiz-Ruiz J., Saez-Navarro C., Bobes J., Baca-Garcia E., Vieta E., Olivares J.M., et al., Efficacy of prospective pharmacogenetic testing in the treatment of major depressive

disorder: Results of a randomized, double-blind clinical trial (2017) *BMC PSYCHIATRY*, 17 (1).

IF: 2.280

Pousa E., Ochoa S., Cobo J., Nieto L., Usall J., Gonzalez B., Garcia-Ribera C., Perez Sola V., Ruiz A.-I., Banos I., Cobo J., Garcia-Ribera C., Gonzalez B., Massons C., Nieto L., Monserrat C., Ochoa S., Pousa E., Ruiz A.-I., Ruiz I., Sanchez-Cabezudo D., Usall J., A deeper view of insight in schizophrenia: Insight dimensions, unawareness and misattribution of particular symptoms and its relation with psychopathological factors (2017) *SCHIZOPHR RES*, 189, 61-68.

IF: 3.649

Puig O., Baeza I., De La Serna E., Cabrera B., Mezquida G., Bioque M., Lobo A., Gonzalez-Pinto A., Parellada M., Corripio I., et al., Persistent negative symptoms in first-episode psychosis: Early cognitive and social functioning correlates and differences between early and adult onset (2017) *J CLIN PSYCHIAT*, 78 (9), 1414-1422.

IF: 4.058

Sampedro F., Revenga M.D.L.F., Valle M., Roberto N., Dominguez-Clave E., Elices M., Luna L.E., Crippa J.A.S., Hallak J.E.C., Araujo D.B.D., Friedlander P., Barker S.A., Alvarez E., Soler J., Pascual J.C., Feilding A., Riba J., Assessing the psychedelic "after-glow" in ayahuasca users: Post-acute neurometabolic and functional connectivity changes are associated with enhanced mindfulness capac-

ities (2017) *INT J NEUROPSYCHOPH*, 20 (9), 698-711.

IF: 3.875

Sanchez-Torres A.M., Moreno-Izco L., Lorente-Omenaca R., Cabrera B., Lobo A., Gonzalez-Pinto A.M., Merchan-Naranjo J., Corripio I., Vieta E., de la Serna E., et al., Individual trajectories of cognitive performance in first episode psychosis: a 2-year follow-up study (2017) *EUR ARCH PSY CLIN N*, 1-13.

IF: 3.390

Santos A., Resmini E., Pascual J.C., Crespo I., Webb S.M., Psychiatric Symptoms in Patients with Cushing's Syndrome: Prevalence, Diagnosis and Management (2017) *DRUGS*, 77 (8), 829-842.

IF: 4.633

Sauras R., Keymer A., Alonso-Solis A., Diaz A., Molins C., Nunez F., Rabella M., Roldan A., Grasa E., Alvarez E., Portella M.J., Corripio I., Volumetric and morphological characteristics of the hippocampus are associated with progression to schizophrenia in patients with first-episode psychosis (2017) *EUR PSYCHIAT*, 45, 1-5.

IF: 3.904

Vega D., Torrubia R., Soto A., Ribas J., Soler J., Pascual J.C., Rodriguez-Fornells A., Marco-Pallares J., Exploring the relationship between non suicidal self-injury and borderline personality traits in young adults (2017) *PSYCHIAT RES*, 256, 403-411.

IF: 2.015

Other Publications

- ▶ Elices M, Soler J, Feliu-Soler A, Carmona C, Tiana T, Pascual JC, García-Palacios A, Álvarez E. Combining emotion regulation and mindfulness skills for preventing depression relapse: a randomized-controlled study. *BORDERLINE PERSONAL DISORD EMOT DYSREGUL*. 2017 Jul 5;4:13.